Synthesis and structure-activity relationship of botryllamides that block the ABCG2 multidrug transporter

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 4, 2010, Pages 1330-1333

  Takada, Kentaro ^a   Imamura, Nobutaka ^a   Gustafson, Kirk R ^b   Henrich, Curtis J ^b,c  

^a RITSUMEIKAN UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

ABCG2 blocker; Natural products; Structure activity relationships; Synthesis

Indexed keywords

BOTRYLLAMIDE F; BOTRYLLAMIDE G; BREAST CANCER RESISTANCE PROTEIN; COUMARIC ACID; FUNCTIONAL GROUP; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BIOLOGICAL ACTIVITY; CHEMICAL BOND; CONJUGATION; DRUG POTENCY; DRUG SYNTHESIS; IC 50; STRUCTURE ACTIVITY RELATION;

ACRYLAMIDES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; COUMARIC ACIDS; HUMANS; MOLECULAR STRUCTURE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; PHENOLS; STRUCTURE-ACTIVITY RELATIONSHIP;

ASCIDIA; BOTRYLLUS;

EID: 75449084213     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.01.016     Document Type: Article

References (13)

1. Dean M., and Annilo T. Annu. Rev. Genom. Human Genet. 6 (2005) 123
2. Robey R.W., Polgar O., Deeken J., To K.W., and Bates S.E. Cancer Metastasis Rev. 26 (2007) 39
3. Calcagno A.M., Kim I.W., Wu C.P., Shukla S., and Ambudkar S.V. Curr. Drug Deliv. 4 (2007) 324
4. Henrich C.J., Bokesch H.R., Dean M., Bates S.E., Robey R., Goncharova E.I., Wilson J.A., and McMahon J.B. J. Biomol. Screen. 11 (2006) 176
5. Jonker J.W., Buitelaar M., Wagenaar E., van der Valk M.A., Scheffer G.L., Scheper R.J., Plosch T., Kuipers F., Oude Elferink R.P.J., Rosing H., Beijnen J.H., and Schinkel A.H. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 15649
6. Abbott B.L. Hematol. Oncol. 21 (2003) 115
7. Henrich C.J., Robey R., Takada K., Bokesch H.R., Bates S.E., Shukla S., Ambudkar S.V., McMahon J.B., and Gustafson K.R. ACS Chem. Biol. 4 (2009) 637
8. Fürstner A., Domostoj M.M., and Scheiper B. J. Am. Chem. Soc. 127 (2005) 11620
9. Snider B.B., Song F., and Foxman B.M. J. Org. Chem. 65 (2000) 793
10. 9 The reaction mixture was purified by reversed-phase HPLC (Cosmosil ARII) to give 1.
11. Kotoku N., Tsujita H., Hiramatsu A., Mori C., Koizumi N., and Kobayashi M. Tetrahedron 71 (2005) 7211
12. Chearwae W., Shukla S., Limtrakul P., and Ambudkar S.V. Mol. Cancer Ther. 5 (2006) 1995
13. PhA was added to NCI-H460/MX20 cells, followed by the appropriate dilutions of synthetic test compound, and the cells were incubated. After removal of the medium and washing with PBS, intracellular fluorescence intensity was read and normalized to cells treated with the ABCG2 inhibitor fumitremorgin C (FTC).